MedUni Wien researcher of the month, Mai 2014

[1]  M. Mayerhoefer,et al.  Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) , 2014, Annals of Hematology.

[2]  M. Raderer,et al.  Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. , 2013, Blood.

[3]  M. Raderer,et al.  Ondansetron for diarrhea associated with neuroendocrine tumors. , 2013, The New England journal of medicine.

[4]  W. Dolak,et al.  A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) , 2013, Haematologica.

[5]  R. Greil,et al.  Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie , 2013, Haematologica.

[6]  U. Jäger,et al.  Subcutaneous dissemination pattern in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma , 2012, Haematologica.

[7]  U. Jaeger,et al.  Plasmacytic differentiation in MALT lymphomas following treatment with rituximab , 2012, Annals of Hematology.

[8]  H. Agis,et al.  Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspects , 2012, Annals of Hematology.

[9]  U. Jaeger,et al.  Second line chemotherapy in patients with enteropathy-associated T cell lymphoma: a retrospective single center analysis , 2011, Annals of Hematology.